GOSS
Gossamer Bio, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.53
−1.50%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$3.93
- Revenue estimate
- $12.2M
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.08
- EPS estimate
- -$0.12
- Revenue actual
- $9.2M
- Revenue estimate
- $3.6M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 6
- EPS misses (12Q)
- 5
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -0.1%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- —
- PT range
- —
- Analysts
- 3
3 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 13, 2026 | -$0.12 | -$0.08 | Beat 35.19% | $9.2M |
| May 18, 2026 | -$0.17 | -$0.20 | Miss -17.65% | $17.0M |
| Mar 17, 2026 | -$0.20 | -$0.21 | Miss -7.32% | $13.8M |
| Nov 5, 2025 | -$0.19 | -$0.21 | Miss -10.53% | $13.3M |
| May 15, 2025 | -$0.18 | -$0.16 | Beat 11.11% | $9.9M |
| Mar 13, 2025 | -$0.17 | -$0.15 | Beat 11.76% | $9.4M |
| Nov 7, 2024 | -$0.18 | -$0.14 | Beat 22.22% | $9.5M |
| Mar 5, 2024 | -$0.20 | -$0.21 | Miss -5.00% | $6.8M |
| Nov 9, 2023 | -$0.20 | -$0.21 | Miss -5.00% | — |
| Mar 17, 2023 | -$0.62 | -$0.59 | Beat 4.84% | — |
| Nov 3, 2022 | -$0.66 | -$0.65 | Beat 1.52% | — |
| Mar 3, 2022 | -$0.74 | -$0.74 | In line | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026